REGiMMUNE

company

About

REGiMMUNE is a biotechnology company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$6M
Industries
Biopharma,Biotechnology,Health Diagnostics
Founded date
Mar 1, 2006
Number Of Employee
1 - 10
Operating Status
Active

REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).

Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.

In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$24.80M
REGiMMUNE has raised a total of $24.80M in funding over 2 rounds. Their latest funding was raised on Feb 1, 2012 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 1, 2012 Series C $5M 1 Daiwa SMBC Capital Detail
May 6, 2008 Series B $8M 1 Detail
Feb 1, 2008 Series B $6M 3 NIF SMBC Ventures Detail
Feb 21, 2007 Series A $4.20M 2 NIF SMBC Ventures Detail
Aug 15, 2006 Seed $1.60M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
4
REGiMMUNE is funded by 4 investors. Daiwa SMBC Capital and NIF SMBC Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Daiwa SMBC Capital Yes Series C
NIF SMBC Ventures Series B
Friendly Partners Series B
Fund Creation Series B